YALE UNIVERSITY
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1701-10-09
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.yale.edu
Examining the Effect of Burosumab on Muscle Function
Phase 4
Completed
- Conditions
- X-linked Hypophosphatemia
- Interventions
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT04146935
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
Phase 2
Withdrawn
- Conditions
- PTLDLymphoid TumorHematopoietic/Lymphoid CancerPlasmacytic Hyperplasia PTLDInfectious MononucleosisFlorid Follicular Hyperplasia PTLDPolymorphic PTLDMonomorphic PTLDClassical Hodgkin Lymphoma Type PTLD
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Yale University
- Registration Number
- NCT04138875
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Opioid and Pain Cognition
Not Applicable
Completed
- Conditions
- Pain
- Interventions
- Behavioral: Cognitive bias modificationBehavioral: Standard attentional bias
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Yale University
- Target Recruit Count
- 20
- Registration Number
- NCT04132609
- Locations
- 🇺🇸
Veteran Affairs Hospital, West Haven, Connecticut, United States
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
Phase 1
Recruiting
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Yale University
- Target Recruit Count
- 100
- Registration Number
- NCT04131829
- Locations
- 🇺🇸
Yale OCD Research Clinic - CMHC/CNRU, 34 Park ST, New Haven, Connecticut, United States
Same-day Discharge After Reconstructive Pelvic Surgery
Not Applicable
Withdrawn
- Conditions
- Reconstructive Pelvic Surgery
- Interventions
- Other: Overnight HospitalizationOther: Same Day Discharge
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Yale University
- Registration Number
- NCT04129541
The Recovery in Stroke Using PAP Study
Not Applicable
Recruiting
- Conditions
- Obstructive Sleep ApneaIschemic Stroke
- Interventions
- Device: PAPBehavioral: HLE
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 360
- Registration Number
- NCT04130503
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Neurobiological Responses in Alcoholism and Early Trauma
Not Applicable
Completed
- Conditions
- Alcohol Use DisorderEarly Trauma Complications
- Interventions
- Behavioral: 8-week outpatient treatment
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Yale University
- Target Recruit Count
- 148
- Registration Number
- NCT04128228
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Investigating Stress-related Mechanisms in the Laboratory and Real World in Individuals With Cannabis Use Disorder
Completed
- Conditions
- Cannabis Use Disorder
- Interventions
- Other: Guided Imagery Laboratory Session
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Yale University
- Target Recruit Count
- 39
- Registration Number
- NCT04116619
- Locations
- 🇺🇸
Yale Stress Center, New Haven, Connecticut, United States
Perinatal Attentional Retraining Intervention for Smoking for Minority Women
Not Applicable
Completed
- Conditions
- Postpartum Smoking Relapse
- Interventions
- Behavioral: Attentional retraining (AR)Behavioral: Visual probe (VP)
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Yale University
- Target Recruit Count
- 22
- Registration Number
- NCT04114877
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Phase 2
Completed
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- Drug: Tumor infiltrating lymphocytes (TIL) LN-145
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Yale University
- Target Recruit Count
- 6
- Registration Number
- NCT04111510
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States